Search Results for: GNPX

Clinical-stage, gene-therapy company Genprex (NASDAQ: GNPX) is developing Oncoprex immunogene therapy as an innovative, gene therapy-based approach for the treatment of non-small cell lung cancer (“NSCLC”). An article further discussing the company reads, “NSCLC is the most common type of lung cancer. It accounts for approximately 85% of all lung-cancer cases, and despite the development … Continue reading “QualityStocksNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Developing Gene Therapy-based Approach to Treat Non-small Cell Lung Cancer”

Genprex (NASDAQ: GNPX) is a clinical-stage, gene-therapy company focused on the advancement of its lead drug candidate, Oncoprex(TM) immunogene therapy. Oncoprex is an investigational therapy for non-small cell lung cancer (“NSCLC”). An article discussing the company reads, “Oncoprex is designed to interrupt cell signaling pathways that cause replication and proliferation of cancer cells, to target … Continue reading “QualityStocksNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Taking Unique Gene Therapy Approach to Cancer Treatment”

Clinical-stage, gene-therapy company Genprex (NASDAQ: GNPX) recently reported that positive preclinical data for the combination of the TUSC2 gene with an anti-PD1 antibody was recorded by its University of Texas MD Anderson Cancer Center collaborators in a lung cancer treatment study (http://ibn.fm/Uws4i). An article discussing the study reads, “The results of the study, which analyzed the … Continue reading “QualityStocksNewsBreaks – Genprex Inc.’s (NASDAQ: GNPX) Collaborators Report Positive Preclinical Data in Lung Cancer Treatment Study”